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Abstract
Background: Enhanced external counterpulsation (EECP) is a non-invasive technique that has
been shown to be effective in reducing both angina and myocardial ischemia in patients not
responding to medical therapy and without revascularization alternatives. The aim of the present
study was to assess the long-term outcome of EECP treatment at a Scandinavian centre, in relieving
angina in patients with chronic refractory angina pectoris.
Methods: 55 patients were treated with EECP. Canadian cardiovascular society (CCS) class,
antianginal medication and adverse clinical events were collected prior to EECP, at the end of the
treatment, and at six and 12 months after EECP treatment. Clinical signs and symptoms were
recorded.
Results: EECP treatment significantly improved the CCS class in 79 ± 6% of the patients with
chronic angina pectoris (p < 0.001). The reduction in CCS angina class was seen in patients with
CCS class III and IV and persisted 12 months after EECP treatment. There was no significant relief
in angina in patients with CCS class II prior to EECP treatment. 73 ± 7% of the patients with a
reduction in CCS class after EECP treatment improved one CCS class, and 22 ± 7% of the patients
improved two CCS classes. The improvement of two CCS classes could progress over a six
months period and tended to be more prominent in patients with CCS class IV. In accordance with
the reduction in CCS classes there was a significant decrease in the weekly nitroglycerin usage (p
< 0.05).
Conclusion: The results from the present study show that EECP is a safe treatment for highly
symptomatic patients with refractory angina. The beneficial effects were sustained during a 12-
months follow-up period.
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Background
Refractory angina pectoris is a clinical diagnosis which is
characterized by chronic angina due to coronary artery
insufficiency in patients who are refractory to conven-
tional forms of treatment [1]. Treatment of coronary
artery disease consists of pharmacological interventions
and invasive actions such as percutaneous coronary inter-
ventions (PCI) and coronary bypass grafting (CABG). In
spite of these generally successful means of treatment the
number of patients with severe symptomatic ischemic
chest pain has increased [2]. It has been reported that up
to 15% of patients with angina pectoris meet the criteria
for refractory angina [3]. This is a significant clinical prob-
lem and the search for alternative therapies have yielded
some new treatments such as Spinal Cord Stimulation
(SCS) [4,5], left stellate ganglion blockade [2,6], thoracic
epidural anesthesia [2,7] and Enhanced External Counter
Pulsation (EECP) [8]. Currently, EECP therapy is one of
the most promising treatments for relieving angina and
has been shown to improve exercise tolerance in patients
with symptoms of stable angina pectoris [9].
EECP is a non-invasive counterpulsation technique,
which uses three sets of pneumatic cuffs wrapped around
the lower extremities. The cuffs are inflated sequentially at
the onset of diastole, producing aortic counter pulsation,
diastolic augmentation, and increased venous return. At
the onset of systole, the external pressure in the cuffs is
released, producing a decrease in systolic pressure. The
hemodynamic effects are similar to intra-aortic balloon
pumping (IABP). In contrast to IABP, EECP provides long-
lasting increase in coronary blood flow [10,11]. A treat-
ment procedure involves 1 to 2 hours/day for a total of 35
hours of therapy. Several studies have shown patient
improvement with lowering in Canadian Cardiovascular
Society Classification (CCS) [12,13]. In addition to reliev-
ing myocardial ischemia, EECP is associated with
improved quality of life [13,14].
The aim of the present study was to evaluate the effect of
EECP treatment at a Scandinavian centre on patients with
refractory angina pectoris. The study was designed to
examine the immediate, six months and 12 months fol-
low-up effects on patients with severe refractory angina in
whom multiple CABG and PCI have already been done
and where further medical and surgical intervention were
exhausted.
Methods
Patients in the study
55 patients, (47 male, 8 female, 45–89 years of age) with
chronic stable refractory angina pectoris that were consec-
utively treated with EECP at the Kristianstad Hospital
were included in this study. Eight patient experienced
adverse events during the EECP treatment which resulted
in termination of their treatment. These patients were not
included in the follow-up investigations. The criteria for
chronic stable refractory angina were defined by Mannhe-
imer and colleagues in 2002 as "a chronic condition char-
acterized by the presence of angina caused by coronary
insufficiency in the presence of coronary artery disease
which cannot be controlled by a combination of medical
therapy, angioplasty and coronary bypass surgery. The
presence of reversible myocardial ischemia should be clin-
ically established to be the cause of the symptoms.
Chronic is defined as a duration of more than 3 months "
[1].
All patients had angiographically proven coronary steno-
sis (> 70%) in at least one major coronary artery and
developed > 1 mm ST-segment depression or positive
scintigraphic defects during exercise. For baseline charac-
teristics and pharmacological treatment of the patients
included in the follow-up study (47 patients), see Table 1
and 2. An informed consent was obtained from all
patients included in the study. The study was performed
in accordance with the Lund University Ethics Commit-
teé.
EECP treatment
The EECP device consists of three paired pneumatic cuffs
applied to the lower extremities (Vasomedical, Westbury,
New York, USA). The cuffs are inflated sequentially
(applying 250–300 mmHg of external pressure) during
diastole, returning blood from the legs to the central cir-
culation, producing aortic diastolic augmentation and
thus increasing both venous return and cardiac output.
The cuffs are then deflated at end-diastole, reducing
peripheral resistance and providing left ventricular
unloading. Daily one hour treatment sessions are typically
administered for a total treatment course of 35 hours.
Data collection
Data on demographics, medical history, coronary disease
status and medication were collected on patients before
EECP treatment. No attempt was made to maintain cur-
rent medication regimens throughout the study, although
patients referred for EECP were considered "optimally
medically managed". CCS class, antianginal medication
use, and adverse clinical events were registered. Patients
were interviewed by telephone six months after their last
EECP treatment session, and 12 months thereafter to
record anginal status and cardiac events.
Calculation and statistics
All calculations and statistics were performed using
GraphpadPrism 4.0. Statistical significance was accepted
when p < 0.05, using student's t-test when comparing two
groups and ANOVA with Dunnett's post hoc test whenBMC Cardiovascular Disorders 2006, 6:28 http://www.biomedcentral.com/1471-2261/6/28
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comparing more than two groups. Values are presented as
means ± S.E.M.
Results
The total cohort completed 36.6 ± 0.5 hours of EECP
treatment. EECP treatment improved the CCS class in
79% of the patients with chronically stable angina pec-
toris (Figure 1). The mean value of CCS classes prior to
EECP treatment were significantly higher as compared to
mean value after EECP treatment (3.0 ± 0.1 as compared
to 2.2 ± 0.1, p < 0.001). The angina functional class did
not change in 21% of the patients and importantly no
patient changed to a higher CCS class directly after EECP
treatment. Most patients (89%) were in CCS class III and
IV pre-EECP treatment and 79% of these patients reduced
their angina with at least one CCS class. The improvement
in CCS class was significant in patients with CCS class III
and IV and persisted six and 12 months after EECP treat-
ment, while there was no such reduction in angina status
in patients with CCS class II (Figure 2). Most patients
improved one CCS class (73 ± 7%), thus 27 ± 7% of the
patients improved two CCS classes and the beneficial
effects were sustained at the 12-months follow-up. The
improvement of two CCS classes tended to be more prom-
inent in patients with CCS class IV prior to the EECP treat-
ment and progressed over a six month period. 86% of the
patients in CCS class IV prior to the EECP treatment
improved in angina functional class. All of the patients
that had improved two CCS classes had done this within
six months after the treatment. During the follow-up
period one patient died six month after EECP treatment in
a myocardial infarction.
The weekly nitroglycerin usage was decreased after EECP
treatment. 87 ± 5% of the patients used nitroglycerin
before EECP treatment and 63 ± 7% used nitroglycerin
after EECP treatment (p < 0.01). The other daily medica-
tion remained unaltered.
All patients underwent the initial phase of the EECP treat-
ment without problems. However, during the EECP treat-
ment period, adverse events were noted in eight cases
which forced them to terminate their treatment (Table 3).
They were not included in the follow-up investigations.
One patient died after 15 treatment sessions. The death
was considered as sudden death with no sign of worsen-
ing of the angina immediately before the death. One
patient suffered from a myocardial infarction between
treatment sessions nine and ten. The patient died in a
myocardial infarction two weeks after termination of the
EECP therapy. Two patients had increased chest pain and
four patients had gastrointestinal problems.
Discussion
The present study is the first long-term systematic follow-
up study from a Scandinavian centre of consecutive
Table 1: Baseline characteristics
Mean age, range (years) 66, 45–89
Gender (men/women) 40/7
Co-existing disease
Heart failure 41%
Hypertension 45%
Diabetes mellitus 22%
Coronary artery disease factors and revascularization status
CAD diagnosis (years; mean, range) 13, 1–35
Prior myocardial infarction 64%
Left ventricular ejection fraction
EF ≥ 50% 59%
40% ≤ EF < 50% 30%
30% ≤ EF < 40% 9%
EF < 30% 2%
Prior PCI 62%
Prior CABG surgery 79%
Prior PCI and CABG surgery 49%
Angina CCS class (% of patients)
I0
II 11%
III 74%
IV 15%
CAD = Coronary Artery Disease, CABG = Coronary Artery Bypass Graft, PCI = Percutaneous Coronary Intervention, CCS = Canadian 
Cardiovascular Society ClassificationBMC Cardiovascular Disorders 2006, 6:28 http://www.biomedcentral.com/1471-2261/6/28
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patients treated with EECP for chronic stable refractory
angina pectoris. The majority of the patients were men
and showed a profile of extensive coronary artery disease,
previous revascularizations and a poor quality of life. The
patients were not available for further coronary revascu-
larization and were on optimal pharmacological treat-
ment. The medical regimen was not changed during the
EECP treatment.
The results from the present study confirm that EECP
treatment significantly reduces the CCS class in patients
with chronic stable angina pectoris, which is in accord-
ance with previous American studies [8,15-17]. It was
noted that there was a significant decrease in the fre-
quency of anginal episodes and nitroglycerin usage. EECP
increases diastolic aortic pressure, reduces systolic pres-
sure and enhances venous return, thus resulting in
increased cardiac output [18]. However, the mechanisms
by which these hemodynamic effects lead to a reduction
of angina are poorly understood, although the effect is
similar to IABP [11]. There is accumulating evidence sug-
gesting that EECP treatment improves endothelial func-
tion, which may contribute to the clinical benefit [12].
EECP treatment is associated with an immediate increase
in blood flow in multiple vascular beds including the cor-
onary arterial circulation [11]. This increase in blood flow
may result in increased endothelial shear stress [19],
which enhances endothelial function by stimulating the
release of the vasodilatory mediator nitric oxide and
reduces the release of the vasocontractile endothelin-1
[18,20-22]. Furthermore, besides the release of metabo-
lites from ischemic regions, an increase in endothelial
shear stress is considered a major stimulus for collateral
blood vessel development and recruitment [23]. This sug-
gests that EECP treatment may exert its clinical beneficial
effect by enhancement of coronary collateralization. EECP
therapy has been associated with the release of angiogenic
factors, such as vascular endothelial growth factor [23],
basic fibroblast growth factor and hepatocyte growth fac-
tor [24].
The relief in CCS class was seen in patients with CCS class
III and IV, while there was no beneficial effect in patients
with CCS class II. Previous studies have shown a benefi-
cial effect even in patients with mild angina [25]. The rea-
son for the lack of effect in patient with CCS class II in the
present study may be due to the limited number of
patients in this group. These results indicate that the EECP
treatment may be more effective in patients with the most
disabling angina, which is in accordance with previous
findings [26]. The reason for this is not known, although
given the important role of shear stress for endothelial
Table 3: Adverse Effects
Patients (gender, age) Number of sessions before termination Cause of termination
Male, 50 12 Increased chest pain
Male, 84 15 Death in myocardial infarction
Female, 57 2 Emesis
Male, 58 6 Hiatus hernia
Male, 53 25 Colics of the bile system
Male, 77 9 Hemorrhoidal problems
Male, 74 25 Chest pain and minor myocardial ischemia
Male, 59 9 Death in myocardial infarction
Table 2: Pharmacological treatment
Medication Baseline
β-blockers 89%
Ca2+ antagonists 51%
Nitroglycerin 87%
1–2 times/week 12%
3–7 times/week 22%
>7 time/week 66%
Anticoagulants 6%
ACEI 45%
ARB 6%
Diuretics 30%
Insulin 9%
Statins 96%
ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin type 1 receptor blockerBMC Cardiovascular Disorders 2006, 6:28 http://www.biomedcentral.com/1471-2261/6/28
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function, the shear stress forces may be stronger in
patients with severe angina as compared to patients with
mild angina [20,21]. Also, it might be easier for a patient
to experience an improvement from CCS class IV to III, as
compared to CCS class II to I, due the classification scale
of the different angina functional classes.
73% of the patients who experience a beneficial effect of
the EECP treatment improved one CCS class, and 27% of
the patients improved two CCS classes. The relief of two
CCS classes tended to progress over a period of six months
and was more prominent in patients with CCS class IV
prior to the EECP treatment. This delayed improvement in
functional angina class has, to our knowledge, never been
reported before. It is furthermore noteworthy that the
improvement persisted in the 12-months follow-up. In a
previous study by Masuda and colleagues it was shown
that the plasma levels of nitric oxide is not increased
immediately after completion of therapy but one month
after [22]. One possible explanation to this delay may be
an up-regulation of the endothelial nitric oxide synthase,
the major source of endothelial nitric oxide [22]. This
would result in a delay of improved endothelial function
[27], and may explain the sustained effect of EECP treat-
ment seen in the present study. Furthermore, the indica-
tion of EECP treatment promoting angiogenesis could
also be an explanation to the delayed and persistent ben-
eficial effect of the current treatment [28].
When stopping medical treatment or physical training no
beneficial effect would be expected in a 12 months follow-
Changes in angina status over a 12-months period in patients with CCS class IV (A), III (B), and II (C) prior to EECP treatments Figure 2
Changes in angina status over a 12-months period in patients with CCS class IV (A), III (B), and II (C) prior to EECP treat-
ments. The figure shows percentage of patients in each CCS class before EECP treatment (100%) and how many (%) of these 
patients that still are in the same CCS class immediately, six months and 12 months after the treatment. n = number of patients 
in the CCS class before EECP treatment. All values were compared to pre-EECP values in each CCS class and are presented as 
mean ± SEM.
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up. Although, long-term effects after EECP treatment have
been confirmed in the present study and in previous clin-
ical [9,13,29] and observational studies [14,18]. The
pathophysiological explanation for the long-term effects
is not fully understood and need further studies. Thus, the
initial improvement in CCS class after EECP therapy
allows more physical activity [29], which may induce sim-
ilar stimuli as EECP treatment [12].
Limitation of the study
The present study is a follow-up report that does not
include a control group, therefore a possible placebo
effect can not be excluded. The improvement in CCS class
could in such a case be a result of special attention of the
patients during the follow-up and also statistically regres-
sion towards mean. The adverse events are in accordance
with what is normally seen in this type of patients and
there was no increase due to the EECP treatment. Thus,
EECP therapy appears to be a promising alternative treat-
ment to patients with severe refractory angina pectoris
where medical treatment and surgical procedures are
exhausted.
Conclusion
The present study is the first to evaluate the effect of EECP
treatment at a Scandinavian centre on patients with refrac-
tory angina pectoris. In summary, we found that EECP is
a safe treatment for highly symptomatic patients with
refractory angina. The effects were sustained in most of the
patients at a 12-months follow-up. These results verify
that the EECP treatment should be considered as an alter-
native treatment for patients with chronic refractory
angina.
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